Showing posts with label antidiabetic. Show all posts
Showing posts with label antidiabetic. Show all posts
Friday, February 22, 2013
Thursday, February 14, 2013
Diabetes Drug Byetta May Offer 'Modest' Weight Loss for Very Obese Teens: Study - Drugs.com MedNews
In continuation of my update Exenatide
Diabetes Drug Byetta May Offer 'Modest' Weight Loss for Very Obese Teens: Study - Drugs.com MedNews
Diabetes Drug Byetta May Offer 'Modest' Weight Loss for Very Obese Teens: Study - Drugs.com MedNews
Labels:
antidiabetic,
antidiabetic drug,
Exenatide. Byetta,
Obesity,
Weight loss
Thursday, July 26, 2012
Investigational diabetes drug appears to improve insulin sensitivity without side effects
Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.
"Current diabetes medications activate a receptor that improves insulin sensitivity, but unfortunately also contributes to side effects that make some people discontinue the medication, contributing to other health problems," says principal investigator Brian N. Finck, PhD. "So even though these drugs are effective, we'd really like to find new insulin-sensitizing therapies that would avoid activating the same receptor."
Finck, a research assistant professor of medicine in the Division of Geriatrics and Nutritional Science, worked with colleagues at the University of Michigan and at the drug discovery company Metabolic Solutions Development Co., LLC. The scientists studied one of the company's investigational drugs, MSD-0602, focusing on its effects in obese mice.
The drug improved blood glucose levels and insulin tolerance in the mice, as did the two diabetes drugs that already are on the market: rosiglitazone (Avandia) and pioglitazone (Actos). All three medications appeared to be about equally effective, but MSD-0602 didn't bind to and activate a receptor in cells called PPARγ. Rather, the investigational drug clings to the mitochondria, part of the cell that produces energy.
"The drug altered the cell's ability to generate energy," Finck says. "And it also seems to have an anti-inflammatory role in the cell. We also found that the drug improved insulin sensitivity in many different kinds of cells including muscle, fat and liver cells."
Next, he and his colleagues will attempt to identify proteins that bind to the mitochondrial membrane. Future therapies then could be developed specifically to bind to those proteins while avoiding activation of the PPARγ pathway.
Investigational diabetes drug appears to improve insulin sensitivity without side effects: Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.
Ref : http://www.jbc.org/content/early/2012/05/23/jbc.M112.363960.full.pdf
Tuesday, April 24, 2012
Liquorice root found to contain anti-diabetic substance
In continuation of my update on Liquorice roots
Liquorice root found to contain anti-diabetic substance
Liquorice root found to contain anti-diabetic substance
Tuesday, August 9, 2011
Diabetes drug rosiglitazone can reduce development of neuropathic pain..
In continuation of my update on Rosiglitazone,
More...
The diabetes drug rosiglitazone (Avandia) can control inflammation leading to nerve damage and abnormal pain responses, claims the researchers of Juntendo University School of Medicine, Tokyo.
As per the claim by the researchers, Rosiglitazone works by blocking a specific pathway—called PPAR-gamma—which appears to play a critical role in the development of disabling neuropathic pain. Researchers therefore propose PPAR-gamma regulation of the macrophage-mediated inflammatory response as a novel therapeutic target for treating neuropathic pain development.
More...
Labels:
antidiabetic,
med-chemist,
PPAR-gamma,
Rosiglitazone (Avandia)
Thursday, July 15, 2010
Cashew Seed Extract an Effective Anti-Diabetic ?
Cashew seed extract (hydroethanolic extract) shows promise as an effective anti-diabetic, according to a new study from the University of Montreal (Canada) and the Université de Yaoundé (Cameroun). The investigation analyzed the reputed health benefits of cashew tree products on diabetes, notably whether cashew extracts could improve the body's response to its own insulin.
The researchers claims that hydroethanolic extract of cashew seed (CSE) and its active component, anacardic acid (see structure), stimulated glucose transport into C2C12 myotubes in a concentration-dependent manner. Extracts of other parts (leaves, bark and apple) of cashew plant were inactive. Significant synergistic effect on glucose uptake with insulin was noticed at 100 g/mL CSE. CSE and AA caused activation of adenosine monophosphate-activated protein kinase in C2C12 myotubes after 6 h of incubation. No significant effect was noticed on Akt and insulin receptor phosphorylation. Both CSE and AA exerted significant uncoupling of succinate-stimulated respiration in rat liver mitochondria.
"Of all the extracts tested (out of leaves, bark, seeds and apples), only cashew seed extract significantly stimulated blood sugar absorption by muscle cells," says senior author Pierre S. Haddad, a pharmacology professor at the University of Montreal's Faculty of Medicine. "Extracts of other plant parts had no such effect, indicating that cashew seed extract likely contains active compounds, which can have potential anti-diabetic properties."
Researchers conclude that, activation of adenosine monophosphate-activated protein kinase by CSE and AA likely increases plasma membrane glucose transporters, resulting in elevated glucose uptake. In addition, the dysfunction of mitochondrial oxidative phosphorylation may enhance glycolysis and contribute to increased glucose uptake. These results collectively suggest that CSE may be a potential anti-diabetic nutraceutical.
Cashew tree products have long been reported to be effective anti-inflammatory agents, counter high blood sugar and prevent insulin resistance among diabetics. This study validates the traditional use of cashew tree products in diabetes and points to some of its natural components that can serve to create new oral therapies...
Subscribe to:
Posts (Atom)